November Giving Report: Moving Forward to Phase 3

November marked the start of what we anticipate will be our final fundraising campaign to raise the remaining $170,000 of the $400,000 required for the purchase of one kilogram of GMP MDMA to be used in our Phase 3 studies of MDMA-assisted psychotherapy for PTSD. We’ve received three generous matches for this campaign so far: $15,000 from Justin Rosenstein, $30,000 from Britt Selvitelle, and $10,000 from the Sarlo Foundation. We’ve already raised over $124,105, 61% of our $174,000 goal. With the help of generous supporters like you, we hope to reach our goal by December 31, 2016.

“Compassion demands that we not deny medicine to the sick,” explains Rosenstein. “I support psychedelic research in the hopes that it will help bring that compassionate care to those who need it most.”

We extend a special thanks to those who so generously supported MAPS this past month:

General Support

  • Nathan Cummings Foundation ($20,000)
  • Audra Foster ($3,000)
  • Douglas & Christine Gehrman Family Foundation ($1,000)
  • Andrew Ryan ($1,000)
  • Flavio Rump ($1,000)
  • Louis B. Bjostad ($1,000)
  • Sahajia Sarkisian ($1,000)
  • Shaun Sutton ($1,000)


  • Ben Warner ($1,000)
  • Hans Petter Sveen ($1,000)
  • Lucy Khoury ($1,000)

Marijuana for PTSD:

  • Julie Holland ($1,202)

Zendo Project:

  • Naval Ravikant ($1,000)
  • Ben Halper ($1,000)

MAPS relies on the generosity of individual donors to achieve our mission. Psychedelic science is again being conducted under federal guidelines, but no funding for psychedelic psychotherapy research is yet available from governments or major foundations that aren’t family foundations. Learn how to how to include MAPS in your will or estate plans. Learn more about hosting a Global Psychedelic Dinner to bring your community together in support of psychedelic science and medicine.